A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma
Relapsed/Refractory Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Dec 2024, none posted yet
Counts until it's fixed
Score over time
- Stage
- Phase 2
- Patients
- 61 (final count)
- Started
- Feb 13, 2023
- Main results expected
- Dec 31, 2024
- Fully finished
- Dec 31, 2024
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose Escalation Phase (Phase IIa):To evaluate the safety, tolerability, and determine the maximum tolerated dose (MTD) and/or RP2D of Tazemetostat in combination with HMPL-689 in patients with R/R lymphoma
Measured over: from Cycle 1 Day 1 up to Cycle 1 Day 28 (each cycle is 28 days)
Dose Expansion Phase (Phase IIb):To evaluate the ORR of Tazemetostat in combination with HMPL-689 in patients with lymphoma
Measured over: from Cycle 1 Day 1 to PFS (each cycle is 28 days)
Dose Expansion Phase (Phase IIb):To evaluate the DCR of Tazemetostat in combination with HMPL-689 in patients with lymphoma
Measured over: from Cycle 1 Day 1 to PFS (each cycle is 28 days)
Dose Expansion Phase (Phase IIb):To evaluate the DOR of Tazemetostat in combination with HMPL-689 in patients with lymphoma
Measured over: from Cycle 1 Day 1 to PFS (each cycle is 28 days)
Dose Expansion Phase (Phase IIb):To evaluate the PFS of Tazemetostat in combination with HMPL-689 in patients with lymphoma
Measured over: from Cycle 1 Day 1 to PFS (each cycle is 28 days)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-12-31, no fading
Raw record changes
- none yet
Trial ID NCT05713110 · record last updated 2025-01-22 · checked 2026-11-09 15:42 UTC